(NYSEMKT: SER) Serina Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.38%.
Serina Therapeutics's earnings in 2026 is -$21,558,000.On average, 2 Wall Street analysts forecast SER's earnings for 2026 to be -$21,357,947, with the lowest SER earnings forecast at -$20,723,552, and the highest SER earnings forecast at -$22,203,806. On average, 2 Wall Street analysts forecast SER's earnings for 2027 to be -$15,904,854, with the lowest SER earnings forecast at -$15,432,433, and the highest SER earnings forecast at -$16,534,749.
In 2028, SER is forecast to generate -$13,632,732 in earnings, with the lowest earnings forecast at -$13,227,799 and the highest earnings forecast at -$14,172,642.